This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Swiss Biobanking Platform | |
|---|---|
| Name | Swiss Biobanking Platform |
| Formation | 2013 |
| Headquarters | Bern, Switzerland |
| Region served | Switzerland |
Swiss Biobanking Platform is a national initiative coordinating biobank integration across Swiss biomedical research. It connects institutional repositories, university hospitals, and national research programs to enable sample sharing, data harmonization, and translational projects. The Platform interacts with international consortia and regulatory bodies to support precision medicine, public health, and translational research across Switzerland.
The Platform operates as a networked infrastructure linking major actors such as University of Bern, ETH Zurich, University of Zurich, University of Geneva, and University of Lausanne with clinical partners including University Hospital Zurich, Lausanne University Hospital, and Geneva University Hospitals. It aligns with national initiatives like Swiss Personalized Health Network and coordinates with European projects such as BBMRI-ERIC, European Molecular Biology Laboratory, and European Bioinformatics Institute to facilitate access to biospecimens, metadata, and standardized protocols. Stakeholders include academic institutions, cantonal authorities, and funding bodies like Swiss National Science Foundation and Innosuisse.
The Platform emerged following strategic recommendations from national studies and roadmaps involving actors such as Federal Office of Public Health (Switzerland), Academy of Medical Sciences (United Kingdom), and advisory groups linked to Human Genome Project stakeholders. Early pilot efforts drew on models from Biobanking and Biomolecular Resources Research Infrastructure and collaborations with research centers including University of Basel and University of Lausanne Faculty of Biology and Medicine. Over time, projects incorporated standards and tools from International Organization for Standardization and guidance from the Council of Europe on human tissue governance.
Governance includes a steering committee with representatives from cantonal hospitals, universities, and funders such as Swiss Confederation agencies and the Swiss Academy of Medical Sciences. Operational subunits engage with registries like ClinicalTrials.gov and ethics offices modelled after committees such as Geneva Canton Ethics Committee. Advisory boards consult with international partners including World Health Organization experts and members of European Commission working groups to ensure interoperability and compliance with transnational regulations such as those influenced by the European Court of Human Rights jurisprudence on bioethics.
Infrastructure covers sample repositories, cold-chain logistics, and laboratory information management systems used across sites like University Hospital of Basel and technology providers with ties to Swiss Federal Institute of Technology in Lausanne. The Platform promotes harmonized specimen handling following protocols from World Health Organization and standards used by National Institutes of Health consortia. Physical biobanks integrate automated storage technologies adopted by biorepository initiatives at institutions like Karolinska Institutet and Cambridge Biomedical Campus partners to enable large-scale cohort support and emergency response samples.
Data governance is structured to align with legal frameworks influenced by Federal Act on Data Protection (Switzerland), while ethics oversight references cases and guidance associated with European Convention on Human Rights and deliberations from bodies such as the European Group on Ethics in Science and New Technologies. The Platform adopts metadata standards compatible with Global Alliance for Genomics and Health APIs and works with bioinformatics centers like Swiss Institute of Bioinformatics and European Bioinformatics Institute to support FAIR principles endorsed by groups including Research Data Alliance and CODATA. Consent models draw on templates used in major cohort studies like UK Biobank and governance mechanisms similar to those in All of Us Research Program.
Collaborations span translational projects with disease-focused networks such as Swiss Multiple Sclerosis Cohort initiatives, oncology consortia affiliated with European Society for Medical Oncology, and infectious disease research units linked to Swiss Tropical and Public Health Institute. The Platform enables cross-institutional studies with partners including Imperial College London, Harvard Medical School, and Max Planck Society groups, facilitating multicentre trials registered in databases such as ClinicalTrials.gov and collaborative grants coordinated through Horizon 2020 and successor programs of the European Commission.
Funding sources include competitive grants from Swiss National Science Foundation, programmatic support from the State Secretariat for Education, Research and Innovation (SERI), and project co-funding from university hospitals and private foundations like the Novartis Foundation and philanthropic entities similar to Wellcome Trust. Long-term sustainability strategies reference business models used by infrastructures such as European Molecular Biology Laboratory and include fee-for-service frameworks, public–private partnerships exemplified by collaborations with biotech firms, and alignment with national health research priorities set by Federal Department of Home Affairs (Switzerland).
Category:Biobanks in Switzerland Category:Medical research organizations in Switzerland